Biogen Inc (BSP:BIIB34)
R$ 169.49 1.36 (0.81%) Market Cap: 149.37 Bil Enterprise Value: 178.06 Bil PE Ratio: 15.80 PB Ratio: 1.56 GF Score: 75/100

Biogen Inc Investor Q&A Call Transcript

Dec 05, 2019 / 10:00PM GMT
Release Date Price: R$202.78 (+23.97%)
Operator

Good evening. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Investor Q&A call following Biogen's CTAD presentation. (Operator Instructions)

Thank you. I would now like to turn the conference over to Mr. Joe Mara, Vice President of Investor Relations. You may begin your conference.

Joe Mara
Biogen Inc. - VP of Finance and Head of IR

Thank you very much, and thank you very much for joining us, and welcome to today's conference call to discuss Biogen's presentation of the top line results from the Phase III studies of aducanumab in early Alzheimer's disease.

Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the slides that will accompany the discussion related to this call. In addition, you will also find the slides presented by Biogen during its CTAD aducanumab webcast, which may be referenced during this call, on the Investors section of biogen.com.

I want to point out that we will be making forward-looking statements,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot